Pages that link to "Q39451354"
Jump to navigation
Jump to search
The following pages link to γ‐Secretase modulators do not induce Aβ‐rebound and accumulation of β‐C‐terminal fragment (Q39451354):
Displaying 12 items.
- Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics (Q26784569) (← links)
- Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data (Q30584453) (← links)
- Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780. (Q33944771) (← links)
- A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease (Q34376103) (← links)
- Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials (Q35695716) (← links)
- Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker (Q36998414) (← links)
- Development and mechanism of γ-secretase modulators for Alzheimer's disease (Q38101383) (← links)
- Novel γ-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012. (Q38123209) (← links)
- New flurbiprofen derivatives: synthesis, membrane affinity and evaluation of in vitro effect on β-amyloid levels (Q39100139) (← links)
- Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology model. (Q48113629) (← links)
- Beyond Chemoselectivity: Catalytic Site-Selective Aldolization of Diketones and Exploitation for Enantioselective Alzheimer's Drug Candidate Synthesis. (Q52962073) (← links)
- Pharmacokinetic and Pharmacodynamic Effects of a γ-Secretase Modulator, PF-06648671, on CSF Amyloid-β Peptides in Randomized Phase I Studies (Q91959894) (← links)